DuoTrav

DuoTrav Adverse Reactions

travoprost + timolol

Manufacturer:

Novartis

Distributor:

Zuellig
/
Firma Chun Cheong
Full Prescribing Info
Adverse Reactions
Summary of the safety profile: In clinical studies involving 2,170 patients treated with DuoTrav eye drops the most frequently reported treatment-related adverse reaction was ocular hyperaemia (12.0%).
Tabulated summary of adverse reactions: The adverse reactions listed in the following table were observed in clinical studies or with post-marketing experience. They are ranked according to system organ class and classified according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), or not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in decreasing order of seriousness. (See Table 1.)

Click on icon to see table/diagram/image

Additional adverse reactions that have been seen with one of the active substances and may potentially occur with DuoTrav eye drops: Travoprost: See Table 2.

Click on icon to see table/diagram/image

Timolol: Like other topically applied ophthalmic medicinal products, timolol is absorbed into the systemic circulation. This may cause undesirable effects similar to those seen with systemic beta-blocking agents. Additional listed adverse reactions include reactions seen within the class of ophthalmic beta-blockers. The incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. For information on how to reduce systemic absorption, see Dosage & Administration. (See Table 3.)

Click on icon to see table/diagram/image

Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in